Boston- Please join us on Wednesday, September 19th, 2018 for an evening of sharing, learning, and socializing with fellow Boston QSP community members at the Boston QSP September Event "Quantitative & Systems Pharmacology (QSP) in Drug Development."
The event will feature a presentation titled "The Future Is So Bright: Quantitative Systems Pharmacology in Drug Discovery & Development" by our distinguished speaker Dr. Cynthia J. (C.J.) Musante. The event will be chaired by Dr. Gianluca Nucci, Vice President, Early Clinical Development, Head of Clinical Pharmacology at Pfizer. Dr. Nucci is also one of our Scientific Advisors at Boston QSP. It will be followed by a mixer and reception where you can enjoy great company and conversation with fellow community members over selected craft beers and food from a local small business.
Registration is free but RSVP is required. The event is sponsored by Novartis.
5:30-6:20 PM: Presentation and Q&A. Presentation title: The Future Is So Bright: Quantitative Systems Pharmacology in Drug Discovery & Development (Havana Room)
6:20-7:30 PM: Mixer & Reception (Venture Café, a few steps down the hallway from the Havana room)
Venue: Cambridge Innovation Center, 1 Broadway, Cambridge.
RSVP here. Limited seats.
* Please do not hesitate to RSVP on the waiting list if the RSVP is full as some guests "un-RSVP" as the event gets closer.
Dr. Musante is the Senior Scientific Director and Head of the Quantitative Systems Pharmacology (QSP) Lab in Pfizer's Internal Medicine Research Unit (IMRU) in Cambridge, MA USA. She obtained her doctoral degree in Applied Mathematics from North Carolina State University and has dedicated the past 18 years to QSP modeling in drug discovery & development. After Entelos Inc, a systems modeling company, Dr. Musante joined Pfizer in 2010 and is leading her lab to develop and utilize QSP models and disease platforms to enhance the robustness and quality of decision-making at the program- and therapeutic strategy-levels, from exploratory research through clinical development.
Dr. Musante is an advocate for model-informed approaches both within and outside of Pfizer. She currently serves as Treasurer and on the Board of Directors for the International Society of Pharmacometrics (ISoP), Conference Chair for the 9th American Conference on Pharmacometrics (ACoP9, Oct.7-10, 2018). She also chaired the inaugural ISoP's QSP Special Interest Group. As a member of the American Society of Clinical Pharmacology & Therapeutics' (ASCPT) Scientific Programming Committee, Dr. Musante is Co-Chair of the pre-conference "Advancing QSP Toward Predictive Drug Development: From Targets to Treatments" that will be held on March 13th at the 2019 ASCPT Annual Meeting. In addition, She serves on the Editorial Board for Clinical Pharmacology and Therapeutics: Pharmacometrics and Systems Pharmacology (CPT:PSP), and co-chairs the IQ Consortium Clinical Pharmacology QSP Working Group.
Quantitative Systems Pharmacology (QSP) is becoming a core component in model-informed drug discovery and development, accelerating and improving the development and utilization of safe and effective new medicines for patients in need. A recent cross-industry survey  conducted by an IQ Consortium Working Group reported a dramatic uptick in the utilization of QSP approaches by pharma and biotech companies following the 2011 publication of the seminal NIH white paper . However, the history of QSP goes back further in time, before QSP was "QSP", and now pharma adopters are routinely reaping the benefits of this approach from exploratory, discovery and development, and post-marketing applications. This talk will give an overview on QSP's past, present, and future, including pioneering and recent case studies from Pfizer, one of QSP's earliest adopters.
 Nijsen M, Wu F, Bansal L, et al. Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape. CPT Pharmacometrics Syst Pharmacol. 2018;7(3):135-146.
 NIH QSP Workshop Group, Sorger P, Allerheiligen SRB, et al. Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms --An NIH White Paper by the QSP Workshop Group--Octber, 2011. Ward R. editor, 2011.
About Boston QSP
Boston QSP is a 501(c)(3) non-profit organization whose mission is to foster the sharing of QSP knowledge, challenges, solutions, and opportunities to advance the field as an interdisciplinary community in Boston.